IMPORTANCE Elevated rates of cancer have been reported in individuals exposed to the World Trade Center (WTC) disaster, including Fire Department of the City of New York (FDNY) rescue and recovery workers.
I ndividuals involved in the rescue and recovery effort at the World Trade Center (WTC) disaster site on and after September 11, 2001 were likely exposed to multiple carcinogenic agents because the WTC dust cloud contained known and potential carcinogens, including asbestos, polycyclic aromatic hydrocarbons, polychlorinated biphenyls, and dioxins. 1, 2 Previously, we and others reported modestly elevated rates of cancer in WTC-exposed rescue and recovery workers compared with general populations. [3] [4] [5] [6] The purpose of this investigation was to project the cohort's future cancer burden by estimating the 20-year incidence of cancer, using both New York City (NYC) cancer rates (modeling impact of aging) and Fire Department of the City of New York WTC Health Program (FDNY-WTCHP) rates (modeling the additional impact of exposure) from the most recent 5-year period for which we had complete cancer data (2007) (2008) (2009) (2010) (2011) . We then used the projected case counts and firstyear medical costs of recently diagnosed cases to develop an approximation of anticipated FDNY-WTCHP spending on initial phase cancer treatment. These estimates of disease burden should inform policy decisions because they offer insights into future needs for monitoring and treatment of WTC-exposed populations.
Methods

Study Population
The FDNY-WTCHP includes 15 507 rescue and recovery workers. The study population was limited to the 14 474 who were alive and free of cancer as of January 1, 2012 . The Montefiore Medical Center and Albert Einstein College of Medicine institutional review board approved this study and waived informed consent. We conducted data analyses starting in March 2016 and completed all analyses by July 2017.
Cancer Rates and Claims Data
We obtained age-, race-and sex-specific NYC cancer rates for the 2007-2011 period from the New York State Cancer Registry. FDNY-WTCHP cancer rates in the white male subpopulation (n = 12 374) were calculated using 2007-2011 FDNY-WTCHP cancer data (includes confirmed cases and state registry matches). We also calculated a second set of FDNY-WTCHP cancer rates for white men that were adjusted for potential surveillance bias, delaying the diagnosis dates of certain cancers by 2 years. Current cancer incidence costs in the FDNY-WTCHP were calculated using the medical claims data of recently diagnosed participants (n = 169).
Statistical Analyses
We used NYC cancer rates and US death rates (obtained from the National Center for Health Statistics 7 ) in simulations to estimate overall and site-specific cancer incidence in the WTCexposed FDNY population from January 1, 2012 , to December 31, 2031 To examine if the calculated FDNY-WTCHP cancer rates would produce different results, we restricted the population to white men and performed the simulations first using NYC rates and then FDNY-WTCHP rates. We then reran this analysis with FDNY-WTCHP rates that were adjusted for possible surveillance bias.
Finally, using the 20-year case counts projected from our primary analysis and the estimated per-patient costs of firstyear cancer care, we created aggregate estimates of the direct medical costs of initial care from January 1, 2012, to December 31, 2031. Data analyses were performed using SAS statistical software (version 9.4; SAS Institute Inc) and Microsoft Excel software. We used t tests to compare mean case counts. Two-sided P <.05 was considered significant. See the Supplement for a detailed eMethods section.
Results
FDNY-WTCHP Population and Cancer Diagnoses
The cohort was 96.8% male and 87.1% white, and the mean (SD) age was 50.2 (9.2) years. Selected demographic characteristics of the cohort as of January 1, 2012 (n = 14 474) , and the white male subgroup (n = 12 374) are displayed in eTable 1 in the Supplement. The Table displays the number of confirmed primary cancer cases diagnosed from September 11, 2001 , to December 31, 2011 .
Estimated 20-Year Cancer Incidence
Based on 2007-2011 NYC rates, the expected number of incident first primary cancer cases from January 1, 2012 , to December 31, 2031 , is 2960 (95% CI, 2883 (Table) . The increasing incidence (95% CI) seen in each 5-year interval over follow-up is due to aging of the population: 2012 to 2016, 560 (95% CI, 524-597); 2017 to 2021 2022 to 2026 and 2027 to 2031, 873 (95% CI, 826-919) .
The FDNY-WTCHP cancer rates projected a modestly higher number of cases in the white male subgroup than did NYC rates (2714 ( [95% CI, 2638 ( -2786 Findings An estimated 2960 new cancer cases in the WTC-exposed cohort (n = 14 474) may occur during this 20-year period. Analyses restricted to white male workers showed greater cancer incidence than would be expected based on NYC rates for this demographic group, corresponding to a significantly elevated number of projected cases (2714 vs 2596).
Meaning
The future cancer burden in WTC-exposed rescue and recovery workers may be greater than expected based on a demographically similar population. 
Financial Burden
Using FDNY-WTCHP mean cancer care cost estimates (eTable 2intheSupplement), the projected aggregate 20-year initial phase medical cost of incident cancers (all-sites) is approximately $235 835 412 (95% CI, $187 582 227-$284 088 597) (in 2015 dollars).
Discussion
Our findings suggest that the FDNY WTC-exposed cohort may experience a greater burden of cancer than would be expected from a population with similar demographic characteristics. The elevated incidence of prostate cancer, thyroid cancer, and melanoma that was observed using FDNY-WTCHP cancer rates is consistent with findings from other cancer studies of WTC-exposed individuals. [3] [4] [5] [6] After FDNY-WTCHP rates for prostate and thyroid cancer were adjusted to partially account for surveillance bias, the resulting cancer counts remained significantly higher than those estimated from NYC rates. Those who performed work at the WTC site may be at increased risk for prostate cancer, thyroid cancer, and melanoma owing to their exposure to carcinogens in the WTC dust. 1, 2, [8] [9] [10] [11] Alternatively, FDNY-WTCHP rates may be elevated owing to insufficient surveillance bias adjustments.
Strengths and Limitations
The projected cancer counts that were produced using FDNY-WTCHP white male rates were based on actual cancers diagnosed from 2007 to 2011. Follow-up time was likely inadequate for the development of WTC-exposure-related cases of some cancer subtypes with long latency periods. For example, lung cancer latency among asbestos-exposed workers has been shown to be 25 to 40 years, 12 and so we expect few WTC-exposure-related lung cancers to be included in the 2007-2011 rates. Conversely, FDNY rates may overestimate the future incidence of cancers with shorter latency periods, such as thyroid and certain hematologic cancers. 13 One limitation specific to the cost analysis was that the use of annual case counts projected by NYC rates instead of FDNY-WTCHP rates meant that we likely overestimated future spending on lung cancer and underestimated that of prostate. In addition, the cost analysis did not examine cancer care that took place more than 12 months after diagnosis, such as distant treatment, surveillance, and end-of-life care. Our cohort may not be fully generalizable to the general WTC-exposed population. It is possible that firefighters have a higher risk of cancer than the general population owing to exposures associated with the occupation.
14 Alternatively, FDNY rescue and recovery workers were a healthy occupational cohort at the time of the WTC disaster, differing from the general population on some characteristics, such as having a lower smoking rate. 15 This may explain the comparatively low FDNY-WTCHP rates of certain cancers, like lung cancer, and may therefore underestimate future cancer incidence and costs. Study strengths include a cohort defined prior to WTC exposure, thereby minimizing enrollment bias; use of 2007-2011 FDNY-WTCHP cancer rates, which exclude prevalent cancers diagnosed shortly after September 11, 2001; and nearly complete matching with tumor registries, minimizing loss to follow-up. Finally, we addressed potential surveillance bias by performing a sensitivity analysis using adjusted FDNY-WTCHP cancer rates.
Conclusions
The projected case counts and costs provide insight into future utilization of cancer resources. Given the elevated incidence of some cancer subtypes observed in this and other WTC-exposed cohorts, it is imperative that WTC-exposed cohorts continue to undergo cancer prevention efforts and screening to reduce this burden and allow for early detection. Patients with cancer, meanwhile, will need access to various treatments. The WTCHP must budget for appropriate resources, given the anticipated increase in cancer incidence, including preventive care, diagnosis, treatment, and cancer-related palliative and end-of-life care. We also advocate for establishing policies to protect the health of workers responding to similar disasters, such as mandating the use of appropriate protective equipment and limiting the amount of time workers can spend at disaster sites. 
eMethods
Study Population
The FDNY-WTCHP includes 15,507 active and retired firefighters and emergency medical service workers. Individuals were considered to be WTC-exposed, and therefore eligible for inclusion in the study cohort, if they were involved in the rescue/recovery effort at the WTC site any time between September 11, 2001 (9/11), and the date of site closure (July 25, 2002) . Data from individuals who before 2012 either developed cancer (n=901) or were cancer-free but died (n=132) were used to determine pre-2012 cancer counts and cohort incidence rates. These 1,033 individuals were excluded from the final study population, which was limited to the at-risk population of 14,474 FDNY-WTCHP participants who were alive and free of cancer as of the beginning of 2012, the first year for which we did not have complete cancer data.
Baseline Characteristics
We assessed participants' race/ethnicity, sex, and age in each year of the study period, as estimation of future cancer cases in the FDNY-WTCHP cohort required the use of recent race-, sex-and age-specific cancer incidence rates. FDNY employees self-report race/ethnicity to FDNY Human Resources, and so we obtained this information from the FDNY Human Resources database, in addition to information on participants' sex and dates of birth.
FDNY Medical Monitoring
Both actively employed and retired WTC-exposed FDNY rescue and recovery workers undergo annual medical monitoring examinations at the FDNY Bureau of Health Services; these involve a pulmonary function test, a complete blood count, chest CT scan (every other year), examination by a physician, and completion of health questionnaires. Information about participants' WTC exposure, or their initial arrival time at the WTC site, was taken from each individual's first post-9/11 monitoring questionnaire.
Regional (NYC) Cancer Rates
We obtained age-, race-and sex-specific cancer rates from the New York State Cancer Registry (NYSCR).
Selecting 2007-2011 NYSCR data for the New York City region, we extracted incidence rates for the most common site-specific cancers in the WTC-exposed cohort, and for all cancers combined. Age-specific rates were grouped in the 5-year bands shown in eTable 1.
FDNY-WTCHP Cancer Rates
Cancer diagnoses that occurred in our cohort before 1/1/2012 were confirmed either by matching to state cancer registries or by a trained clinician's (NJ) review of medical records. Since over 85% of individuals enrolled in the FDNY-WTCHP are white males, we were able to calculate stable, age-specific cohort cancer rates only for this subgroup. A cancer diagnosis that occurred between 1/1/2007 and 12/31/2011 in the white male subgroup was considered an incident case of a site-specific cancer if it was the first instance of a malignant tumor at that site.
When determining the number of cancers at all sites, a diagnosis was added to the total case count if it was the first tumor of any cancer subtype (including bladder in-situ) recorded for an individual. Nonmalignant tumors and skin carcinomas (basal or squamous cell) were excluded from this case definition. The calculated cancer rates were used in an analysis in which we compared the future incidence estimates that resulted from using these rates to estimates produced by NYC rates for the white male subgroup (N=12,374).
Cases of prostate, lung, bladder, kidney, thyroid, and the hematologic cancers (Hodgkin lymphoma, nonHodgkin lymphoma, leukemia, multiple myeloma, and other hematopoietic cancers) may be detected earlier in the FDNY-WTCHP cohort than they would be in a general population, due to the routine screening procedures (blood tests, chest CT scans) that are part of FDNY medical monitoring. In order to create a second set of FDNY-WTCHP rates that were adjusted for potential surveillance bias, we identified pre-2012 cases of the above-mentioned cancers that were diagnosed less than six months after routine monitoring (N=118) and delayed the diagnosis dates of these cases by two years. A two-year lag in diagnosis date was used because previous research showed that two years was the average screening lead time for prostate cancer diagnosis. 1 We then recalculated the 2007-2011 rates of the aforementioned cancer types and of all cancers combined in white males. Since there are no specific screening procedures to detect colorectal cancer or melanoma performed during the monitoring examinations, we did not create adjusted rates for these cancers.
Claims Data
Cancer incidence costs in the FDNY-WTCHP were calculated using the medical claims data of individuals without previous cancer diagnoses who developed cancer in 2014 or 2015 and received services through FDNY-WTCHP (N=169). We defined the initial cost of each patient's care as the sum of the amounts paid for all medical procedures and medications billed within one year after the diagnosis date. 2, 3 The claims data includes healthcare services that were authorized by the FDNY-WTCHP and performed by WTCHP providers. Providers submit claims for services to the FDNY claims processing team. Services are paid for by the WTCHP, which is run by the National Institute for Occupational Safety and Health (NIOSH), an agency of the Centers for Disease Control and Prevention (CDC).
Deaths
Death dates of WTC-exposed rescue/recovery workers were obtained from the FDNY database. These dates were utilized when calculating person-time for the 2007-2011 FDNY-WTCHP cancer rates, and to determine cohort members alive on 1/1/2012. Age-specific mortality rates, used to predict deaths in the cohort, were obtained from the National Center for Health Statistics (NCHS).
Statistical Analyses
We entered NYC cancer rates and NCHS death rates into simulations to estimate the 20-year cancer incidence in the study population. In each simulation, instances of cancer and death were determined by random number generators that used the Poisson distribution and each individual's demographic-specific rates. Cancer events were summed to determine the total case counts for each simulation. We performed the simulation 1,000 times for each cancer subtype to obtain mean incidence estimates and 95% confidence intervals (CIs).
For the subgroup analysis, we restricted the results from the simulations to only include cancers occurring in white males. Simulations were repeated using the calculated FDNY-WTCHP rates in place of NYC rates. To examine the possibility that some of the cancer counts produced by FDNY rates might be affected by surveillance bias, we conducted a sensitivity analysis in which we re-ran the simulations for all cancers combined and for prostate, hematologic, lung, thyroid, kidney, and bladder cancer with FDNY rates that were adjusted for possible early cancer detection.
The financial burden of incident cancer in the full cohort was approximated by multiplying the mean medical costs of initial cancer care with the 20-year case counts projected in our primary analysis; this created aggregate estimates of the direct medical costs (in 2015 dollars) of initial care from 1/1/2012-12/31/2031. Since costs of specific treatment procedures increase due to the adoption of new technologies, 2 our calculated mean treatment costs were increased by 2% for every year through 2031.
eResults
FDNY-WTCHP Population Characteristics and Cancer Diagnoses
Of the 14,474 individuals included in the main study population, 14,007 (96.8) were male, and 88.3%
(12,374) of males were white. The white male subgroup was similar to the full cohort in age, smoking status, education, and WTC exposure level, but had a greater proportion of firefighters.
Between 9/11 and 12/31/2011, the most commonly diagnosed cancer type in the FDNY-WTCHP population was prostate, followed by the combined hematologic cancers, melanoma, colorectal, thyroid, bladder, and lung and kidney cancer (Table) . There were too few incident cases (<20) at other cancer sites to investigate separately.
Estimated 20-year Cancer Incidence in FDNY-WTCHP Population When examining the future cancer incidence per five-year time interval, we observed that the number of newly occurring cases was projected to be highest during 2027-2031, the final five years (873 cases, 95% CI: 826-919). The five largest contributors to the estimated future cancer burden were prostate, lung, hematologic, colorectal and bladder cancer. 
